IS5374A - Aðferðir og lyfjablöndur til ýmiss konar læknismeðferðar þar sem notuð eru gen sem umrita seytt prótín á borð við interferón-beta - Google Patents

Aðferðir og lyfjablöndur til ýmiss konar læknismeðferðar þar sem notuð eru gen sem umrita seytt prótín á borð við interferón-beta

Info

Publication number
IS5374A
IS5374A IS5374A IS5374A IS5374A IS 5374 A IS5374 A IS 5374A IS 5374 A IS5374 A IS 5374A IS 5374 A IS5374 A IS 5374A IS 5374 A IS5374 A IS 5374A
Authority
IS
Iceland
Prior art keywords
methods
pharmaceutical compositions
interferon
genes
beta
Prior art date
Application number
IS5374A
Other languages
English (en)
Other versions
IS2318B (is
Inventor
G. Barsoum James
Xiao Qin Albert
Original Assignee
Biogen Idec Ma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Ma Inc. filed Critical Biogen Idec Ma Inc.
Publication of IS5374A publication Critical patent/IS5374A/is
Publication of IS2318B publication Critical patent/IS2318B/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IS5374A 1997-08-29 2000-02-11 Aðferðir og lyfjablöndur til ýmiss konar læknismeðferðar þar sem notuð eru gen sem umrita seytt prótín á borð við interferón-beta IS2318B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5725497P 1997-08-29 1997-08-29
PCT/US1998/017606 WO1999010516A2 (en) 1997-08-29 1998-08-25 Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta

Publications (2)

Publication Number Publication Date
IS5374A true IS5374A (is) 2000-02-11
IS2318B IS2318B (is) 2007-11-15

Family

ID=22009467

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5374A IS2318B (is) 1997-08-29 2000-02-11 Aðferðir og lyfjablöndur til ýmiss konar læknismeðferðar þar sem notuð eru gen sem umrita seytt prótín á borð við interferón-beta

Country Status (25)

Country Link
EP (1) EP1007717B8 (is)
JP (3) JP4124565B2 (is)
KR (1) KR100699285B1 (is)
CN (1) CN100342019C (is)
AT (1) ATE316145T1 (is)
AU (1) AU740428B2 (is)
BR (1) BR9812138A (is)
CA (1) CA2300480C (is)
CY (1) CY1105029T1 (is)
CZ (2) CZ297314B6 (is)
DE (1) DE69833264T2 (is)
DK (1) DK1007717T3 (is)
EA (1) EA003256B1 (is)
EE (1) EE04873B1 (is)
ES (1) ES2257817T3 (is)
HK (1) HK1029599A1 (is)
HU (1) HU224422B1 (is)
IL (2) IL134593A0 (is)
IS (1) IS2318B (is)
NO (1) NO20000990L (is)
NZ (1) NZ503401A (is)
PT (1) PT1007717E (is)
SK (1) SK286821B6 (is)
TR (1) TR200000532T2 (is)
WO (1) WO1999010516A2 (is)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002056918A2 (en) 2001-01-22 2002-07-25 Biogen, Inc. Method of enhancing delivery of a therapeutic nucleic acid
US8058248B2 (en) * 2001-04-26 2011-11-15 The United States Of America As Represented By The Secretary Of Agriculture Foot and mouth disease virus vaccine comprising interferons
CN1388248A (zh) * 2001-05-25 2003-01-01 钱其军 高效表达干扰素的肿瘤细胞内特异性增殖的腺病毒及其构建方法
EP1835032A1 (en) * 2006-03-14 2007-09-19 Université de Liège A self-inactivating recombinant lentiviral vector for the inhibition of HIV replication
MD36Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului ductal in situ neinvaziv al glandei mamare
MD24Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului neinvaziv al glandei mamare
MD35Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de apreciere a riscului dezvoltării carcinomului neinvaziv in situ al glandei mamare
MD23Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului lobular in situ neinvaziv al glandei mamare
CN103505722B (zh) * 2012-06-19 2016-04-13 苏州丁孚靶点生物技术有限公司 干扰素在治疗/预防对常规抗肿瘤疗法有抗性的肿瘤中的用途及相关的产品和方法
WO2017214706A1 (en) * 2016-06-15 2017-12-21 Tissue Regeneration Therapeutics Inc. Anti-cancer use of genetically modified human umbilical cord perivascular cells (hucpvc)
EP3976073A4 (en) * 2019-06-01 2023-08-02 Sivec Biotechnologies, LLC BACTERIAL PLATFORM FOR DELIVERING GENE EDITING SYSTEMS TO EUKARYOT CELLS

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2122519C (en) * 1994-04-29 2001-02-20 Rudolf Edgar Dr. Falk Cancer treatment and metastasis prevention
CA2156132A1 (en) * 1994-08-16 1996-02-17 Abraham Bout Recombinant vectors derived from adenovirus for use in gene therapy
US5952221A (en) * 1996-03-06 1999-09-14 Avigen, Inc. Adeno-associated virus vectors comprising a first and second nucleic acid sequence

Also Published As

Publication number Publication date
CN100342019C (zh) 2007-10-10
JP4124565B2 (ja) 2008-07-23
CZ299095B6 (cs) 2008-04-23
JP2001514010A (ja) 2001-09-11
DK1007717T3 (da) 2006-05-29
AU740428B2 (en) 2001-11-01
JP2005225888A (ja) 2005-08-25
CY1105029T1 (el) 2010-03-03
EP1007717B1 (en) 2006-01-18
BR9812138A (pt) 2000-07-18
NO20000990L (no) 2000-05-02
SK286821B6 (sk) 2009-06-05
SK2482000A3 (en) 2000-08-14
JP4219335B2 (ja) 2009-02-04
AU9205198A (en) 1999-03-16
IS2318B (is) 2007-11-15
KR20010023511A (ko) 2001-03-26
CA2300480C (en) 2010-01-05
HK1029599A1 (en) 2001-04-06
CN1271391A (zh) 2000-10-25
EA003256B1 (ru) 2003-02-27
CA2300480A1 (en) 1999-03-04
EP1007717A2 (en) 2000-06-14
DE69833264D1 (de) 2006-04-06
ATE316145T1 (de) 2006-02-15
EP1007717B8 (en) 2006-05-03
TR200000532T2 (tr) 2000-11-21
PT1007717E (pt) 2006-06-30
EE04873B1 (et) 2007-08-15
IL134593A0 (en) 2001-04-30
HU224422B1 (hu) 2005-08-29
CZ2000733A3 (cs) 2000-06-14
NZ503401A (en) 2003-01-31
ES2257817T3 (es) 2006-08-01
HUP0002913A3 (en) 2003-08-28
EE200000102A (et) 2000-12-15
HUP0002913A2 (hu) 2000-12-28
KR100699285B1 (ko) 2007-03-26
JP3953458B2 (ja) 2007-08-08
WO1999010516A2 (en) 1999-03-04
DE69833264T2 (de) 2006-09-28
WO1999010516A3 (en) 1999-05-06
NO20000990D0 (no) 2000-02-28
IL134593A (en) 2007-06-17
JP2004155786A (ja) 2004-06-03
CZ297314B6 (cs) 2006-11-15
EA200000270A1 (ru) 2000-10-30

Similar Documents

Publication Publication Date Title
CY1105029T1 (el) Μεθοδοι και συνθεσεις για θεραπειες καρκινου χρησιμοποιωντας γονιδια που κωδικοποιουν εκκρινομενες πρωτεϊνες οπως ιντερφερονη-βητα
DE69426328T2 (de) Verwendung von mesothelialen zellen in der gentherapie
DK0559884T4 (da) Rekombinante virusvektorer til ekspression i muskelceller
DE69630890D1 (de) Peptid-immitierende substanzen in der krebstherapie
FI962154A (fi) Koostumus terapeuttisten tuotteiden in vivo valmistusta varten
DK1093383T3 (da) Lægemiddelafgivelsessystem omfattende et homeobox-peptid og et cytotoksisk eller antineoplastisk lægemiddel
WO1999032516A3 (en) Pharmaceutical compositions containing the long pentraxin ptx3
DK1144600T3 (da) Akt-3-nukleinsyre, polypeptider og anvendelser deraf
NO991839L (no) FremgangsmÕter og preparater for utlevering og ekspresjon av interferon-<alfa>-nukleinsyrer
IL128569A0 (en) Fibroblast growth factor homologous factor S(FHFs) and methods of use
DE69910809D1 (de) Verwendung von OmpA Enterobakterproteinen um zielgerichtet Antigen-Präsentierende Zellen anzusteuern
AU590861B2 (en) New human lymphotoxin (TNF-beta) polypeptides their prepartion and use
HUP0400340A2 (hu) Polipeptidek immunogenitásának csökkentésére szolgáló eljárások